HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.

AbstractOBJECTIVE:
The effectiveness of anthelminthic and corticosteroid drug therapy in parenchymal neurocysticercosis is well established. The treatment of parenchymal solitary cysticercus granuloma (SCG), however, remains controversial. We attempted to obtain a consistent estimate of the efficacy of anthelminthic and corticosteroid drug treatment in SCG.
METHODS:
Randomized-controlled trials (RCTs) comparing rates of seizure freedom, granuloma resolution, and residual calcification in individuals with SCG treated with anthelminthic or corticosteroid drugs with those treated with antiepileptic drugs (AEDs) alone were systematically reviewed and quantified using fixed- or random-effects meta-analysis.
RESULTS:
Fifteen RCTs were identified for inclusion. Ten RCTs assigned 765 people with SCG to AED treatment with or without anthelminthic drug (albendazole) treatment. A further 5 RCTs assigned 457 people with SCG to AED treatment with or without corticosteroid drugs. Anthelminthic treatment was associated with significantly increased rates of seizure freedom (nonevent odds ratio: 2.45; 95% confidence interval: 1.49-4.03; p = 0.0004) and significantly higher rates of granuloma resolution (odds ratio: 2.09; 95% confidence interval: 1.41-3.00; p = 0.0003), but did not alter the risk of residual calcification. Corticosteroid treatment was not significantly associated with any outcome.
CONCLUSIONS:
Anthelminthic treatment with albendazole provides improved rates of seizure freedom and hastens resolution of the granuloma. The role of corticosteroid treatment remains uncertain. The benefits (or lack thereof in the case of corticosteroids) are consistent when measured across different time points after treatment.
AuthorsWillem M Otte, Monika Singla, Josemir W Sander, Gagandeep Singh
JournalNeurology (Neurology) Vol. 80 Issue 2 Pg. 152-62 (Jan 08 2013) ISSN: 1526-632X [Electronic] United States
PMID23269591 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
Chemical References
  • Anthelmintics
  • Anti-Inflammatory Agents
  • Praziquantel
  • Prednisolone
  • Albendazole
Topics
  • Adolescent
  • Albendazole (therapeutic use)
  • Anthelmintics (therapeutic use)
  • Anti-Inflammatory Agents (therapeutic use)
  • Calcinosis (prevention & control)
  • Child
  • Child, Preschool
  • Female
  • Granuloma (drug therapy)
  • Humans
  • Infant
  • Male
  • Neurocysticercosis (drug therapy)
  • Odds Ratio
  • Praziquantel (therapeutic use)
  • Prednisolone (therapeutic use)
  • Randomized Controlled Trials as Topic
  • Seizures (epidemiology, etiology)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: